Eyenovia Inc Total Assets
Eyenovia Inc total assets. Based on the latest financial reports, Eyenovia Inc (EYEN) holds total assets worth $5.98 Million USD as of March 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Eyenovia Inc (EYEN) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Eyenovia Inc (2015–2024)
Total assets of Eyenovia Inc from 2015 to 2024. This chart illustrates how Eyenovia Inc's total assets have evolved over time, based on quarterly financial data. See EYEN live share price for real-time trading data and today's change.
Eyenovia Inc - Asset Composition Analysis
Eyenovia Inc Total Assets Breakdown (December 2024)
Eyenovia Inc total assets breakdown as of December 2024. Eyenovia Inc's total assets of $5.98 Million consist of 75.5% current assets and 24.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 57.8% |
| Accounts Receivable | $313.53K | 8.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how Eyenovia Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Eyenovia Inc (EYEN) liquidity to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Eyenovia Inc's current assets represent 75.5% of total assets in 2024, a decrease from 99.5% in 2015.
- Cash Position: Cash and equivalents constituted 57.8% of total assets in 2024, down from 88.4% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2015.
- Asset Diversification: The largest asset category is accounts receivable at 8.6% of total assets.
Eyenovia Inc Competitors by Total Assets
Key competitors of Eyenovia Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Eyenovia Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.34 | 0.83 | 3.99 |
| Quick Ratio | 0.34 | 0.61 | 4.05 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-9.94 Million | $-2.86 Million | $8.24 Million |
Eyenovia Inc - Advanced Valuation Insights
This section examines the relationship between Eyenovia Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 36.17 |
| Latest Market Cap to Assets Ratio | 19.98 |
| Asset Growth Rate (YoY) | -87.3% |
| Total Assets | $3.67 Million |
| Market Capitalization | $73.30 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Eyenovia Inc's assets at a significant premium (19.98x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Eyenovia Inc's assets decreased by 87.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Eyenovia Inc (2015–2024)
The table below shows the annual total assets of Eyenovia Inc from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $3.67 Million | -87.26% |
| 2023-12-31 | $28.78 Million | -7.27% |
| 2022-12-31 | $31.04 Million | -1.97% |
| 2021-12-31 | $31.66 Million | -6.63% |
| 2020-12-31 | $33.91 Million | +130.70% |
| 2019-12-31 | $14.70 Million | -26.57% |
| 2018-12-31 | $20.02 Million | +254.68% |
| 2017-12-31 | $5.64 Million | +64.39% |
| 2016-12-31 | $3.43 Million | +21.80% |
| 2015-12-31 | $2.82 Million | -- |
About Eyenovia Inc
Eyenovia, Inc., an ophthalmic technology company, engages in development and commercialization of ophthalmic solutions in the United States. The company offers Optejet, a topical ophthalmic medication dispensing platform services. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vi… Read more